Skip to main content
Log in

Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

  • Systematic Review
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly, and close associations between AD and diabetes have been found. Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, as newly-developed oral hypoglycaemic agents, were evaluated as a possible therapy for AD.

Aim

We systematically evaluated the efficacy and safety of PPAR-γ agonists in the treatment of AD and amnestic mild cognitive impairment (aMCI), the prodromal stage of AD.

Methods

A search of the electronic databases PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure (until July 2014) was conducted, and included randomized controlled trials. Dichotomous data were expressed as risk ratios (RRs) with 95 % confidence intervals (CIs), and continuous data were expressed as mean differences (MD) with 95 % CIs. The results were pooled using a random-effects model.

Results

Nine eligible studies were identified, with 4,327 participants. Using the Alzheimer’s Disease Assessment Scale–Cognitive subscale, pioglitazone was found to be efficacious, especially for patients with comorbid diabetes (MD −3.47, 95 % CI −4.40 to −2.54). Rosiglitazone was not efficacious, even for apolipoprotein E (APOE) ε4 non-carriers (MD −0.31, 95 % CI −1.12 to 0.51). There was no increase in any adverse events (AEs) or serious AEs compared with placebo. Peripheral edema was the most frequent AE related to PPAR-γ agonist treatment (RR 4.14, 95 % CI 2.37–7.23).

Conclusions

There is insufficient evidence to support the use of rosiglitazone in aMCI and AD patients in order to improve cognitive performance. Nonetheless, the efficacy of pioglitazone seems to be promising, particularly for patients with comorbid diabetes, however this needs to be further confirmed by well-designed trials with large sample sizes. PPAR-γ agonists such as rosiglitazone and pioglitazone are generally well-tolerated in AD and aMCI patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Liu J, Wang LN, Tan JP. Dementia in China: current status. Neurology. 2013;81:1077–8.

    Article  PubMed  Google Scholar 

  2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–7.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026–36.

    Article  PubMed Central  PubMed  Google Scholar 

  4. van Exel E, Eikelenboom P, Comijs H, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry. 2009;66:1263–70.

    Article  PubMed  Google Scholar 

  5. Schapira AH. Mitochondrial diseases. Lancet. 2012;379:1825–34.

    Article  CAS  PubMed  Google Scholar 

  6. Roriz-Filho JS, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792:432–43.

  7. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia. 2009;52:1031–9.

    Article  CAS  PubMed  Google Scholar 

  8. Pilcher H. Alzheimer’s disease could be “type 3 diabetes”. Lancet Neurol. 2006;5:388–9.

    Article  PubMed  Google Scholar 

  9. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440–8.

    Article  CAS  PubMed  Google Scholar 

  10. Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999;56:1135–40.

    Article  CAS  PubMed  Google Scholar 

  11. Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 2014;10:S47–54.

    Article  PubMed  Google Scholar 

  12. van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets. 2010;14:1029–45.

  13. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs. 2008;22:1–14.

    Article  CAS  PubMed  Google Scholar 

  14. Shibata N, Motoi Y, Tomiyama H, et al. Lack of genetic associations of PPAR-gamma and PGC-1alpha with Alzheimer’s disease and Parkinson’s disease with dementia. Dement Geriatr Cogn Disord Extra. 2013;3:161–7.

    Article  Google Scholar 

  15. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org. Accessed 22 June 2014.

  16. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68:45–50.

    PubMed  Google Scholar 

  17. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57:177–9.

    Article  PubMed  Google Scholar 

  18. Hanyu H, Sato T, Sakurai H, Iwamoto T. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer’s disease. J Am Geriatr Soc. 2010;58:1000–1.

    Article  PubMed  Google Scholar 

  19. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011;32:1626–33.

    Article  CAS  PubMed  Google Scholar 

  20. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res. 2011;8:592–606.

    Article  CAS  PubMed  Google Scholar 

  22. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6:246–54.

    CAS  PubMed  Google Scholar 

  23. Tzimopoulou S, Cunningham VJ, Nichols TE, et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2010;22:1241–56.

    CAS  PubMed  Google Scholar 

  24. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950–8.

    PubMed  Google Scholar 

  25. Takeda Study Registration. About the TOMMORROW study (NCT01931566). Tommorrowstudy.com. 2013. Available from: http://www.tommorrowstudy.com/TommorrowStudy.aspx#.VEem_HDexN0. Accessed 22 June 2014.

  26. Liu J, Wang LN. Caregivers of patients with dementia in Chinese mainland: a retrospective analysis. Am J Alzheimers Dis Other Demen. 2013;28:679–81.

    Article  CAS  PubMed  Google Scholar 

  27. Liu J, Wang LN, Tan JP, et al. Burden, anxiety and depression in caregivers of veterans with dementia in Beijing. Arch Gerontol Geriatr. 2012;55:560–3.

    Article  PubMed  Google Scholar 

  28. Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. JAMA. 2014;311:1052–60.

    Article  CAS  PubMed  Google Scholar 

  29. Moon JH, Kim HJ, Yang AH, et al. The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012;15:135–42.

    Article  CAS  PubMed  Google Scholar 

  30. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann Pharmacother. 2011;45:1416–24.

    Article  CAS  PubMed  Google Scholar 

  31. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2014;(1):CD010693.

  32. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–201.

    Article  CAS  PubMed  Google Scholar 

  33. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Jia Liu, Jian-ping Jia and Lu-ning Wang state no conflicts of interest, and have received no payment for the preparation of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jia Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, J., Wang, Ln. & Jia, Jp. Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Drugs Aging 32, 57–65 (2015). https://doi.org/10.1007/s40266-014-0228-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0228-7

Keywords

Navigation